Long acting systemic HIV pre-exposure prophylaxis: an examination of the field (Q39371494)

11 September 2017

1 reference

title

Long acting systemic HIV pre-exposure prophylaxis: an examination of the field (English)

1 reference

11 September 2017

0 references

Ellen Luecke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612340%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Daniel Johengen

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612340%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Tejal A Desai

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612340%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

publication date

13 June 2017

1 reference

Drug delivery and translational research

11 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612340%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612340%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612340%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

805-816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612340%20AND%20SRC:MED&resulttype=core&format=json

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Tenofovir-based preexposure prophylaxis for HIV infection among African women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Preexposure prophylaxis for HIV infection among African women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Delivery of long-acting injectable antivirals: best approaches and recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Injectable agents for pre-exposure prophylaxis: lessons learned from contraception to inform HIV prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Long-acting injectable antiretrovirals for HIV treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Long-Acting Antiretrovirals: Where Are We now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Stated product formulation preferences for HIV pre-exposure prophylaxis among women in the VOICE-D (MTN-003D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Improved delivery of poorly soluble compounds using nanoparticle technology: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Nanosuspensions in drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Drug nanoparticles: formulating poorly water-soluble compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Nanosizing: a formulation approach for poorly-water-soluble compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Ultra-long-duration local anesthesia produced by injection of lecithin-coated tetracaine microcrystals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Formulation and pharmacology of long-acting rilpivirine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Long-acting antiviral agents for HIV treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Cabotegravir long-acting for HIV-1 prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Long-acting rilpivirine for HIV prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Antibody-based concepts for multipurpose prevention technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Enhanced antibody half-life improves in vivo activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

The origins and evolution of "controlled" drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Breakthrough discoveries in drug delivery technologies: the next 30 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Reservoir-based drug delivery systems utilizing microtechnology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

An overview of clinical and commercial impact of drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Controlled drug delivery systems: past forward and future back

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

A single histrelin implant is effective for 2 years for treatment of central precocious puberty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Nexplanon: the new implant for long-term contraception. A comprehensive descriptive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Determinants of drug delivery and transport to solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Removal of etonogestrel contraceptive implants in the operating theater: report on 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

The pathology of the foreign body reaction against biomaterials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Macrophages, Foreign Body Giant Cells and Their Response to Implantable Biomaterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Contraceptive devices: subcutaneous delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Polycaprolactone thin-film drug delivery systems: Empirical and predictive models for device design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

The biocompatibility manifesto: biocompatibility for the twenty-first century

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Diffusion in confined geometries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Nanostructured thin film polymer devices for constant-rate protein delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Leveraging nanochannels for universal, zero-order drug delivery in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound as tested in rats and dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Development of a vaginal delivery film containing EFdA, a novel anti-HIV nucleoside reverse transcriptase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Implantable controlled release systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Polyurethane-based drug delivery systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Polymers for the controlled release of macromolecules: effect of molecular weight of ethylene-vinyl acetate copolymer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

THIN SILICONE MEMBRANES-THEIR PERMEATION PROPERTIES AND SOME APPLICATIONS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Effects of heat treatment on the permeability of polyvinyl alcohol films to a hydrophilic solute

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

The in vivo degradation, absorption and excretion of PCL-based implant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Mechanisms of polymer degradation in implantable devices. I. Poly(caprolactone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Long-acting hormonal contraceptives for women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Biodegradable poly(ether ester urethane)urea elastomers based on poly(ether ester) triblock copolymers and putrescine: synthesis, characterization and cytocompatibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Delivering enhanced testosterone replacement therapy through nanochannels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

DUROS technology delivers peptides and proteins at consistent rate continuously for 3 to 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Prioritizing multipurpose prevention technology development and investments using a target product profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Implanon®: user views in the first year across three family planning services in the Trent Region, UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

The Promise of Intravaginal Rings for Prevention: User Perceptions of Biomechanical Properties and Implications for Prevention Product Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Learning from the private sector: towards a keener understanding of the end-user for microbicide introduction planning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Hormonal contraceptive discontinuation patterns according to formulation: investigation of associations in an administrative claims database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Assessing regional differences in contraceptive discontinuation, failure and switching in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Contraceptive implants: providing better choice to meet growing family planning demand

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Scaling up delivery of contraceptive implants in sub-Saharan Africa: operational experiences of Marie Stopes International

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Cost-effectiveness of pre-exposure prophylaxis targeted to high-risk serodiscordant couples as a bridge to sustained ART use in Kampala, Uganda

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Evolution of implantable and insertable drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Controlled release technologies for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Methodological lessons from clinical trials and the future of microbicide research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Long-acting and permanent contraception: an international development, service delivery perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Regulatory challenges in developing long-acting antiretrovirals for treatment and prevention of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Drug/device combinations for local drug therapies and infection prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Nanosuspension Technologies for Delivery of Poorly Soluble Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13346-017-0391-6

Zero-order controlled-release polymer matrices for micro- and macromolecules

21 January 2018

1 reference

12 December 2020

Physical stability of ethyl diatrizoate nanocrystalline suspension in steam sterilization

1 reference

12 December 2020

Mass Transport Properties of Co(polyether)polyurethane Membranes I: Preparation and Characterization

1 reference

12 December 2020

1. Commentary on an exponential model for the analysis of drug delivery: Original research article: a simple equation for description of solute release: I II. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres,

1 reference

12 December 2020

Insertion and removal of Implanon

1 reference

12 December 2020

Poly-epsilon-caprolactone intravitreous devices: an in vivo study

1 reference

12 December 2020

Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development

1 reference

12 December 2020

10.1007/S13346-017-0391-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612340%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28612340%20AND%20SRC:MED&resulttype=core&format=json